Project description
A new non invasive stimulation technology to keep neurological patients moving
Neurological and neurodegenerative diseases, like stroke and Parkinson's disease, often result in impaired mobility, affecting a patient’s quality of life and ability to carry out activities of daily living. Lack of mobility reduces a person's independence and social interactions, and puts the patient at higher risk for secondary complications as well, including cardiovascular disease and diabetes. Automated Mechanical Peripheral Stimulation (AMPS) is a therapeutic approach to stimulate the peripheral nervous system, and the Swiss SME that developed it has integrated it into small units like boots to be worn for short periods of time by the patient in the comfort of their home to receive the AMPS treatment. With two treatments per week lasting only about 2 minutes each, clinical trials demonstrate an important improvement in motor symptoms. EU funding of the GONDOLA AMPS project is helping the company prepare to commercialise their patented technology and expand globally.
Objective
Neurological conditions such as Parkinson’s and cerebral stroke cause motor disabilities, resulting in walking and balance impairment. These disorders severely affect patient’s independence and quality of life. State-of-the-art treatments and medications have little or no effect. Gondola AMPS is a game-changing proprietary medical device by Gondola Medical Technologies that delivers Automated Mechanical Peripheral Stimulation (AMPS). After treatment, most patients experience a drastic improvement of their motor symptoms. This non-invasive treatment takes less than two minutes and two applications a week are sufficient for a long-lasting effect. Gondola AMPS has already been adopted by 450 patients in several countries; boosted self-confidence and quality of life are consistently reported. The treatment can be delivered at home via a personalised device or at medical settings with a multi-patient device.
In the EU only, more than 7 million Parkinson patients and stroke survivors are affected by long-term disabilities and this will continue to grow at a rapid pace. Mobility losses and related care, equipment and infrastructure, bear huge costs estimated to represent an annual €50+ billion. Gondola AMPS contributes to addressing this major economic and societal challenge. The invention is patent-protected in several countries. Ten clinical trials and as many peer-reviewed scientific publications conclude to the effectiveness of Gondola AMPS at strongly improving motor symptoms. Gondola AMPS brings a non-invasive and cost-effective answer to a widespread unmet medical need. Break-even is planned in less than three years while making Gondola Medical Technologies a global leader. To support this strong growth more than 150 highly qualified jobs will be created across Europe and eventually in USA, Canada and Japan.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesbasic medicineneurologystroke
- medical and health sciencesbasic medicineneurologyparkinson
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME - SME instrumentCoordinator
1066 EPALINGES
Switzerland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.